Author/Authors :
Hosono، نويسنده , , Osamu and Homma، نويسنده , , Toshio and Kobayashi، نويسنده , , Hiroshi and Munakata، نويسنده , , Yasuhiko and Nojima، نويسنده , , Yoshihisa and Iwamoto، نويسنده , , Aikichi and Morimoto، نويسنده , , Chikao، نويسنده ,
Abstract :
Human plasma contains soluble CD26/dipeptidyl peptidase IV (sCD26/DPPIV) although its physiological significance remains unclear. To determine whether the plasma sCD26 levels have clinical relevance in HIV-1 infected individuals, the concentration and DPPIV enzyme activity of plasma sCD26 were measured. While there is no significant difference between the plasma levels of sCD26 in 90 HIV-1 infected individuals and in 79 uninfected controls, specific DPPIV enzyme activity of sCD26 was significantly decreased in HIV-1 infected individuals (P< 0.0001). Specific DPPIV enzyme activity was correlated with the levels of CD4+T cells (r= 0.247;P< 0.02), CD8+T cells (r= 0.236;P< 0.03), and adenosine deaminase (r= 0.227;P< 0.05) and had an inverse correlation with HIV-1 RNA (Spearmanʹsr= 0.474;P= 0.0012). Furthermore, recombinant sCD26 enhanced thein vitroPPD-induced response of lymphocytes from HIV-1 infected individuals with decreased specific DPPIV enzyme activity. These results suggest that the specific DPPIV enzyme activity of plasma sCD26 may contribute to the immunopathogenesis of HIV infection.